Last edition
News about "Alebund Pharmaceuticals"
Alebund Receives US FDA IND Clearance for IgA Nephropathy Drug Candidate AP308
Alebund Pharmaceuticals has received US FDA IND clearance for AP308, an engineered recombinant IgA protease, paving the way for first-in-human clinical testing in IgA nephropathy.
Alebund Pharmaceuticals | 10/09/2026 | By News Bureau | 110
Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.
Alebund Pharmaceuticals | 07/05/2026 | By News Bureau | 190
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy